系统性硬化症相关间质性肺病的治疗:美国胸科学会循证临床实践指南
该指南由24名风湿病学、系统性硬化症、肺病学、间质性肺疾病及方法学专家组成的国际委员会制定,采用GRADE方法评估系统综述证据。委员会推荐使用霉酚酸酯,建议使用环磷酰胺、利妥昔单抗、托珠单抗、尼达尼布及尼达尼布联合霉酚酸酯,并呼吁进一步研究吡非尼酮及吡非尼酮联合霉酚酸酯的安全性和有效性。
要点
- 推荐使用霉酚酸酯治疗系统性硬化症相关间质性肺病。
- 建议使用环磷酰胺、利妥昔单抗、托珠单抗、尼达尼布及尼达尼布联合霉酚酸酯。
- 呼吁进一步研究吡非尼酮及吡非尼酮联合霉酚酸酯的安全性和有效性。
核心结论
- 委员会推荐使用霉酚酸酯治疗系统性硬化症相关间质性肺病患者。
- 委员会建议使用环磷酰胺、利妥昔单抗、托珠单抗、尼达尼布及尼达尼布联合霉酚酸酯。
- 委员会呼吁进一步研究吡非尼酮及吡非尼酮联合霉酚酸酯的安全性和有效性。
研究设计与样本
- 国际专家指南委员会由24名在风湿病学、系统性硬化症、肺病学、间质性肺疾病或方法学方面具有专长且有个⼈经验的成员组成。
- 委员会讨论了使用GRADE方法评估的已发表证据的系统综述。
- 推荐仅由无利益冲突的专家组成员做出,并考虑了效应估计的置信度、结局重要性、利弊平衡、成本、可行性、可接受性及健康公平性影响。
关键数值与推荐
- 推荐使用霉酚酸酯。
- 建议使用环磷酰胺。
- 建议使用利妥昔单抗。
- 建议使用托珠单抗。
- 建议使用尼达尼布及尼达尼布联合霉酚酸酯。
临床怎么用
- 该指南为临床医生和患者进行知情和共享决策提供循证基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based. Methods: An international expert guideline committee composed of 24 individuals with expertise in rheumatology, SSc, pulmonology, ILD, or methodology, and with personal experience with SSc-ILD, discussed systematic reviews of the published evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Predetermined conflict-of-interest management strategies were applied, and recommendations were made for or against specific treatment interventions exclusively by the nonconflicted panelists. The confidence in effect estimates, importance of outcomes studied, balance of desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications for health equity were all considered in making the recommendations. This was in accordance with the American Thoracic Society guideline development process, which is in compliance with the Institute of Medicine standards for trustworthy guidelines. Results: For treatment of patients with SSc-ILD, the committee: 1) recommends the use of mycophenolate; 2) recommends further research into the safety and efficacy of (a) pirfenidone and (b) the combination of pirfenidone plus mycophenolate; and 3) suggests the use of (a) cyclophosphamide, (b) rituximab, (c) tocilizumab, (d) nintedanib, and (e) the combination of nintedanib plus mycophenolate. Conclusions: The recommendations herein provide an evidence-based clinical practice guideline for the treatment of patients with SSc-ILD and are intended to serve as the basis for informed and shared decision making by clinicians and patients.
引用
- Raghu G, Montesi SB, Silver RM, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024. PMID: 37772985. doi:10.1164/rccm.202306-1113ST
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。